LEAP THERAPEUTICS, INC. (CYPH) Stock Analysis — April 2026 Rating, Price, and Forecast
Company Overview — What Does LEAP THERAPEUTICS, INC. Do?
Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap Therapeutics, Inc. has an option and license agreement with BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts. LEAP THERAPEUTICS, INC. (CYPH) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Doug E. Onsi and employs approximately 40 people. With a market capitalization of $69M, CYPH is one of the notable companies in the Healthcare sector.
LEAP THERAPEUTICS, INC. (CYPH) Stock Rating — Reduce (April 2026)
As of April 2026, LEAP THERAPEUTICS, INC. receives a Reduce rating with a composite score of 26.7/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.CYPH ranks #2,788 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, LEAP THERAPEUTICS, INC. ranks #386 of 838 stocks, placing it in the upper half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).
CYPH Stock Price and 52-Week Range
LEAP THERAPEUTICS, INC. (CYPH) currently trades at $1.03. The stock gained $0.03 (3.1%) in the most recent trading session. The 52-week high for CYPH is $3.70, which means the stock is currently trading -72.2% from its annual peak. The 52-week low is $0.22, putting the stock 363.3% above its annual trough. Recent trading volume was 4.6M shares, reflecting moderate market activity.
Is CYPH Overvalued or Undervalued? — Valuation Analysis
LEAP THERAPEUTICS, INC. (CYPH) carries a value factor score of 24/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The trailing price-to-earnings ratio is 14.27x, compared to the Healthcare sector average of 23.63x — a discount of 40%. The price-to-book ratio stands at 0.43x, versus the sector average of 2.75x.
At current multiples, LEAP THERAPEUTICS, INC. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.
LEAP THERAPEUTICS, INC. Profitability — ROE, Margins, and Quality Score
LEAP THERAPEUTICS, INC. (CYPH) earns a quality factor score of 10/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -34.9%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -32.8% versus the sector average of -33.1%.
Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.
CYPH Debt, Balance Sheet, and Financial Health
LEAP THERAPEUTICS, INC. has a debt-to-equity ratio of 6.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 35.56x, indicating strong short-term liquidity. Total debt on the balance sheet is $0. Cash and equivalents stand at $10M.
CYPH has a beta of 2.03, meaning it is more volatile than the broader market — a $10,000 investment in CYPH would be expected to move 102.8% more than the S&P 500 on any given day. The stability factor score for LEAP THERAPEUTICS, INC. is 8/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.
LEAP THERAPEUTICS, INC. Revenue and Earnings History — Quarterly Trend
In TTM 2026, LEAP THERAPEUTICS, INC. reported revenue of $0 and earnings per share (EPS) of $0.07. Net income for the quarter was $-54M. Operating income came in at $-54M.
In FY 2025, LEAP THERAPEUTICS, INC. reported revenue of $0 and earnings per share (EPS) of $0.07. Net income for the quarter was $5M. Operating income came in at $-41M.
In Q3 2025, LEAP THERAPEUTICS, INC. reported revenue of $0 and earnings per share (EPS) of $-0.08. Net income for the quarter was $-3M. Operating income came in at $-3M.
In Q2 2025, LEAP THERAPEUTICS, INC. reported revenue of $0 and earnings per share (EPS) of $-0.40. Net income for the quarter was $-17M. Operating income came in at $-17M.
Over the past 8 quarters, LEAP THERAPEUTICS, INC. has experienced revenue contraction from $0 to $0. Investors analyzing CYPH stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.
CYPH Dividend Yield and Income Analysis
LEAP THERAPEUTICS, INC. (CYPH) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.
CYPH Momentum and Technical Analysis Profile
LEAP THERAPEUTICS, INC. (CYPH) has a momentum factor score of 51/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 40/100 reflects moderate short selling activity.
CYPH vs Competitors — Healthcare Sector Ranking and Peer Comparison
Within the Healthcare sector, LEAP THERAPEUTICS, INC. (CYPH) ranks #386 out of 838 stocks based on the Blank Capital composite score. This places CYPH in the upper half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.
Comparing CYPH against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full CYPH vs S&P 500 (SPY) comparison to assess how LEAP THERAPEUTICS, INC. stacks up against the broader market across all factor dimensions.
CYPH Next Earnings Date
No upcoming earnings date has been announced for LEAP THERAPEUTICS, INC. (CYPH) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.
Should You Buy CYPH? — Investment Thesis Summary
The quantitative profile for LEAP THERAPEUTICS, INC. suggests caution. The quality score of 10/100 flags below-average profitability. The value score of 24/100 indicates premium valuation. High volatility (stability score 8/100) increases portfolio risk.
In summary, LEAP THERAPEUTICS, INC. (CYPH) earns a Reduce rating with a composite score of 26.7/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on CYPH stock.
Related Resources for CYPH Investors
Explore more research and tools: CYPH vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare CYPH head-to-head with peers: CYPH vs AZN, CYPH vs SLGL, CYPH vs VMD.